Mounting evidence has demonstrated the efficacy of mannan-BAM, Toll-like receptor (TLR) ligands, and anti-CD40 monoclonal antibodies (MBTA) vaccines in generating an anti-tumor response in solid tumors [1,2]. This evidence concerns the gene CD40 and neoplasm.